The mean survival in patients with ≥ 40% of HER2-positive tumor cells was 20.5 months (95% CI 15.6–32.6) vs. 11.4 months (95% CI 9.3–15.0; HR 0.46). The gene discussed is ERBB2; the disease is neoplasm.